Director/PDMR Shareholding
30 Mar 2026 16:00 CEST
Issuer
NOVACYT
Avertissement aux actionnaires:
Une version en français de ce document sera publiée dès que
possible.
Novacyt S.A.
("Novacyt" or the "Company")
Director/PDMR Shareholding
Paris, France, and Manchester, UK - 30 March 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it has been notified that, on 26 and 27 March 2026, the following Directors purchased ordinary shares of €1/15 each in the Company (the "Ordinary Shares"):
| Director | Title | Number of Ordinary Shares purchased | Average price paid per Ordinary Share | Resultant beneficial holding | % of issued share capital |
| Lyn Rees | CEO | 73,379 | €0.3899 | 73,379 | 0.00% |
| John Brown | Chairman | 73,762 | €0.3899 | 73,762 | 0.00% |
| Ian Gilham | NED | 28,750 | £0.34415 | 28,750 | 0.00% |
Contacts
| Novacyt SA | https://novacyt.com/investors | |||
| Lyn Rees, Chief Executive Officer | Via Walbrook PR | |||
| Steve Gibson, Chief Financial Officer | ||||
| SP Angel Corporate Finance LLP (Nominated Adviser and Broker) | +44 (0)20 3470 0470 | |||
| Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) |
||||
| Singer Capital Markets (Joint Broker) | +44 (0) 20 7496 3000 | |||
| Phil Davies / James Fischer / Samed Ethemi | ||||
| Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit |
+33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com |
|||
| Walbrook PR (Financial PR & IR) Paul McManus / Lianne Applegarth Alice Woodings |
+44 (0)20 7933 8780 or novacyt@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7584 391 303 +44 (0)7407 804 654 |
|||
About Novacyt Group (www.novacyt.com)
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.
The Company is divided into three business segments:
| Clinical | Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
|
| Instrumentation | Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
|
| Research Use Only | Range of services for the life sciences industry:
|
Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer to the website: www.novacyt.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||||||||||
| a) | Name 1) Lyn Rees 2) John Brown 3) Ian Gilham |
1) CEO 2) Chairman 3) NED |
||||||||||||||||||||
| 2. | Reason for the Notification | |||||||||||||||||||||
| a) | Position/status | See 1(a) - classified as a PDMR of the Company | ||||||||||||||||||||
| b) | Initial notification/ Amendment | Initial Notification | ||||||||||||||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||
| a) | Name | Novacyt S.A. | ||||||||||||||||||||
| b) | LEI | 213800BWAC2BF295EG28 | ||||||||||||||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||||||||||
| a) | Description of the Financial instrument, type of instrument | ordinary shares of €1/15 each | ||||||||||||||||||||
| Identification code | FR0010397232 | |||||||||||||||||||||
| b) | Nature of the transaction | Acquisition of Ordinary Shares | ||||||||||||||||||||
| c) | Price(s) and volume(s) 1) Lyn Rees 2) John Brown 3) Ian Gilham |
|
||||||||||||||||||||
| d) | Aggregated information: · Aggregated volume · Price 1) Lyn Rees 2) John Brown 3) Ian Gilham |
|
||||||||||||||||||||
| e) | Date of the transaction | 1 & 2) 26 and 27 March 2026 3) 27 March 2026 |
||||||||||||||||||||
| f) | Place of the transaction | 1 & 2) Euronext and 3) AIM | ||||||||||||||||||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
- SECURITY MASTER Key: m3CfY5xpZG6dlptrk8mWnGhqm29klpXHlmaVlWWaZ5rFcG9olJppbpqYZnJol2xn
- Check this key: https://www.security-master-key.com.
Regulated information:
Inside Information:
- other releases
Full and original press release in PDF: https://www.actusnews.com/news/97271-6769y.pdf
Source
NOVACYT
Provider
ActusNewsWire
Company Name
NOVACYT
ISIN
FR0010397232
Symbol
ALNOV
Market
Euronext Growth